Noviosense

Noviosense is pioneering a novel approach to glucose monitoring by developing a tear-based sensor designed to sit comfortably behind the lower eyelid. The company has successfully completed a Phase 2 clinical trial demonstrating correlation between tear and blood glucose and has initiated a second validation study in type 1 diabetics. Founded in 2016 and backed by venture capital, Noviosense is seeking strategic partners and funding to accelerate development toward a targeted market entry, positioning itself to disrupt the large and growing diabetes management market with a truly non-invasive solution.

A non-invasive sensor platform that measures biomarkers in tears. The core device is a small, flexible, enzymatically-based sensor placed in the lower eyelid, powered and read wirelessly via NFC, using a smart hydrogel coating for biocompatibility and comfort.

Noviosense competes in the glucose monitoring space dominated by large players like Dexcom and Abbott (subcutaneous CGMs) and Roche and LifeScan (blood glucose meters). Its primary differentiation is true non-invasiveness (ocular vs. subcutaneous or capillary). It also faces potential competition from other non-invasive technologies in development, such as spectroscopic or transdermal approaches.